Current medical research and opinion
-
Randomized Controlled Trial
User experiences with second-generation 32-gauge x 4 mm vs. thinner comparator pen needles: prospective randomized trial.
Two similarly designed studies compared user experiences with a second-generation extra-thin-wall, 5-bevel 32 G × 4 mm pen needle (PN) with redesigned hub versus four thinner commercially available PNs. ⋯ The investigational 32 G PN was associated with less participant-reported injection pain and less perceived dose delivery force compared with four thinner PNs, suggesting no additional pain reduction or force reduction benefit conferred by the thinner PNs.
-
Randomized Controlled Trial Multicenter Study
Safety and efficacy of galcanezumab in Taiwanese Patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine.
Migraine is a chronic, disabling neurological disease affecting >1 billion people worldwide. Migraine remains undertreated in Asia, including Taiwan. Galcanezumab is a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide, a peptide firmly established in the pathophysiology of migraine, with demonstrated efficacy and safety in patients with episodic or chronic migraine. Our objective was to evaluate the efficacy and safety of galcanezumab in Taiwanese patients with episodic or chronic migraine. ⋯ Galcanezumab is a promising therapeutic for the preventive treatment of migraine in the Taiwanese population.